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Background: We evaluated the effects of two dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and vildagliptin, on metabol-
ic parameters in patients with type 2 diabetes mellitus.
Methods: A total of 170 type 2 diabetes patients treated with sitagliptin or vildagliptin for more than 24 weeks were selected. The 
patients were separated into two groups, sitagliptin (100 mg once daily, n=93) and vildagliptin (50 mg twice daily, n=77). We 
compared the effect of each DPP-4 inhibitor on metabolic parameters, including the fasting plasma glucose (FPG), postprandial 
glucose (PPG), glycated hemoglobin (HbA1c), and glycated albumin (GA) levels, and lipid parameters at baseline and after 24 
weeks of treatment.
Results: The HbA1c, FPG, and GA levels were similar between the two groups at baseline, but the sitagliptin group displayed a 
higher PPG level (P=0.03). After 24 weeks of treatment, all of the glucose-related parameters were significantly decreased in 
both groups (P=0.001). The levels of total cholesterol and triglycerides were only reduced in the vildagliptin group (P=0.001), 
although the sitagliptin group received a larger quantity of statins than the vildagliptin group (P=0.002).The mean change in the 
glucose- and lipid-related parameters after 24 weeks of treatment were not significantly different between the two groups (P=not 
significant). Neither sitagliptin nor vildagliptin treatment was associated with a reduction in the high sensitive C-reactive protein 
level (P=0.714). 
Conclusion: Vildagliptin and sitagliptin exert a similar effect on metabolic parameters, but vildagliptin exerts a more potent 
beneficial effect on lipid parameters.
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INTRODUCTION
The increasing prevalence of diabetes mellitus is increasing the 
economic burden of controlling blood glucose levels and 
treating complications [1,2]. Diabetes mellitus patients also 
exhibit a more than 3-fold greater risk of cardiovascular dis-
ease (CVD) and mortality than nondiabetic subjects [3]. To 
prevent CVD, patients with diabetes mellitus require compre-
hensive treatment that includes the control of glucose, blood 
pressure and cholesterol levels. The UK Prospective Diabetes 
Study demonstrated that intensive glucose control of type 2 
diabetes could prevent microvascular complications [4]. How-
ever, large follow-up clinical studies revealed that intensive 
treatment increases the risk of CVD and mortality due to hy-
poglycemia and weight gain [5-7]. Therefore, a variety of po-
tential drugs have been developed to control the glucose levels 
and reduce severe hypoglycemia. Among these drugs, dipepti-
dyl peptidase-4 (DPP-4) inhibitors have been proven effective 
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for glucose control without inducing hypoglycemia and are 
widely used as the primary therapeutic option. Sitagliptin is the 
first DDP-4 inhibitor that was commercially approved for use. 
Many clinical trials demonstrated that sitagliptin reduces the 
level of glycated hemoglobin (HbA1c) by 0.6% to 1.5% com-
pared to placebo in subjects of various ages and ethnicities [8-
10]. Vildagliptin, the second DPP-4 inhibitor developed, also 
effectively reduces the plasma glucose levels [11,12]. Although 
both sitagliptin and vildagliptin belong to the same class of 
DPP-4 inhibitors, these two drugs display many different prop-
erties, including structure, pharmacokinetics and mechanism 
of action to inhibit DPP-4 [13-15]. Sitagliptin is a 523.32 Da 
compound that contains a pyrimidine structure and displays a 
12.4-hour half-life. It is primarily metabolized by cytochrome 
p450 3A4 and eliminated by renal excretion [13]. Alternatively, 
vildagliptin is a 303 Da compound that contains a cyanopyri-
dine structure and displays a 2-hour half-life. Because of its low 
protein binding affinity (9%), vildagliptin is rapidly absorbed, 
reaching its peak plasma concentration within 1 hour, and then 
rapidly eliminated [14]. However, despite its short half-life, 
vildagliptin exerts a potent inhibitory effect for 24 hours by co-
valently binding to the DPP-4 receptor if administered at a 
dose of 50 mg twice daily [15,16]. Generally, the effect of both 
drugs on the plasma glucose level and the glucose indices is 
similar. Vildagliptin exerts a more potent beneficial effect on 
the levels of oxidative stress and inflammation markers [17,18]. 
However, few patients were examined for only a short dura-
tion, so the long-term effects of both drugs on metabolic pa-
rameters have not been well studied.
 This study investigated the effects of two DPP-4 inhibitors, 
sitagliptin and vildagliptin, on metabolic parameters in pa-
tients with type 2 diabetes mellitus.
METHODS
This retrospective study reviewed patients who had been diag-
nosed with type 2 diabetes mellitus from January 2008 to De-
cember 2012 at Severance Hospital Diabetes Center. Patients 
who were receiving 100 mg of sitagliptin once daily or 50 mg 
of vildagliptin twice daily were selected and the dosage of each 
patient’s previous medications was maintained. The exclusion 
criteria were as follows: 1) any change in prior medications 
just before (the past 12 weeks) or during the period of DPP-4 
inhibitor treatment, including any alteration in dose, composi-
tion, or frequency; 2) chronic liver (Child-Pugh C) or kidney 
disease (stage ≥IV); or 3) any medications that could affect 
the plasma glucose levels, such as a steroid, thyroid hormone, 
or herbal drug. The enrolled patients were separated into the 
sitagliptin group or the vildagliptin group according the drug 
that they were receiving. The metabolic parameters, including 
the levels of fasting plasma glucose (FPG), postprandial 
2-hour glucose (PPG), HbA1c, glycated albumin (GA), total 
cholesterol, high density lipoprotein cholesterol (HDL-C), low 
density lipoprotein cholesterol (LDL-C), triglyceride (TG), 
and creatinine, were measured at baseline and every 12 weeks 
during the 24-week study. The high sensitivity C-reactive pro-
tein (hsCRP) assay was also performed. The prevalence of hy-
pertension, coronary artery occlusive disease (CAOD), pe-
ripheral artery occlusive disease (PAOD) and stroke and the 
medical history of statin administration were recorded using 
the medical records. The FPG levels were determined via the 
standard glucose oxidase method using a 747 automatic ana-
lyzer (Hitachi, Tokyo, Japan). The HbA1c levels were mea-
sured via high performance liquid chromatography. The se-
rum GA level was determined via an enzymatic method using 
an albumin-specific proteinase, ketoamine oxidase, and albu-
min assay reagent (LUCICA GA-L; Asahi Kasei Pharma Co., 
Tokyo, Japan), as well as a Hitachi 7699 Pmodule autoanalyzer 
(Hitachi Instruments Service, Tokyo, Japan). The fasting and 
postprandial 2-hour insulin and C-peptide levels were mea-
sured via a radioimmunoassay method at baseline. To analyze 
insulin resistance and insulin secretion, homeostatic model as-
sessment-insulin resistance (HOMA-IR) and the change in the 
C-peptide level were calculated as follows: HOMA-IR= fasting 
insulin (μU/mL)×FPG (mmol/L)/22.5, and ∆C-peptide= 
postprandial 2-hour C-peptide–fasting C-peptide. The body 
mass index (BMI) was also calculated according to the follow-
ing equation: BMI=weight (kg)/height2 (m2). The mean change 
(∆) in each metabolic parameter was calculated using following 
formula: level after 24 weeks of treatment–level at baseline. 
Statistical analysis
All descriptive data were expressed as the means±standard 
deviation. Continuous variables of the sitagliptin group and 
the vildagliptin group were compared and analyzed using t-
tests. Nominal variables were compared using the chi-square 
test. Analyses of more than three measured parameters were 
performed using repeated measures analysis of variance. P val-
ues of less than 0.05 were considered to be statistically signifi-
cant. Pearson correlation coefficient (r) was used to assess the 
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strength of the relationships between the clinical and laborato-
ry variables. Variables displaying P<0.05 based on univariate 
analysis were subjected to multivariate analysis. SPSS version 
17.0 (SPSS Inc., Chicago, IL, USA) was used for the analyses.
RESULTS
Baseline characteristics
A total of 170 patients suffering from type 2 diabetes mellitus 
who had received sitagliptin or vildagliptin for more than 24 
weeks were selected. Ninety-three patients were taking sita-
gliptin, and 77 patients were taking vildagliptin. The baseline 
characteristics of both groups are presented in Table 1. The 
mean age of the subjects was 61.3±12.9 years in the sitagliptin 
group and 58.7±12.2 years in the vildagliptin group (P= 
0.186). The diabetes mellitus duration was over 6 years in both 
groups (P=0.642). There was no difference in the metabolic 
parameters of the FPG, HbA1c, GA, creatinine, estimated glo-
merular filtration rate, TG or total, and LDL-C or HDL-C level 
at baseline. However, the PPG level was significantly higher in 
the sitagliptin group than in the vildagliptin group (P=0.030). 
Although HOMA-IR was not different between the groups 
(P=0.480), the postprandial 2-hour C-peptide level and the 
change in the C-peptide level were significantly higher in the 
subjects taking vildagliptin than in those taking sitagliptin 
(P=0.030). There was no significant difference in the preva-
lence of hypertension, CAOD, PAOD, or stroke (P=not signif-
icant) between the groups. Statins were more frequently ad-
ministered in the sitagliptin group than in the vildagliptin 
group (P=0.002).
Change in the metabolic parameters after 24 weeks of 
treatment
After 24 weeks of DPP-4 inhibitor treatment, all of the glucose 
parameters were significantly decreased compared to baseline 
in both groups (Table 2). The HbA1c and GA levels were sig-
nificantly decreased compared to the premedication levels 
(Fig. 1A and B). The ratio of GA to HbA1c was significantly 
reduced from 2.5 to 2.3 (P=0.001). There were changes in 
both the FPG and PPG levels (Fig. 1C and D). However, there 
was no significant difference between the groups in the mag-
nitude of the change in the glucose parameters (Table 2). The 
total cholesterol and TG levels were significantly decreased in 
the vildagliptin group (P=0.001) (Fig. 1E and F) regardless of 
statin use (Supplementary Table 1). The LDL-C level was also 
reduced, although this result was not statistically significant 
(P=0.077). There was no significant change in the lipid pa-
rameters in the sitagliptin group (Table 2). Although the mean 
changes in the lipid parameters were not significantly different 
between the two groups, vildagliptin displayed a trend to re-
duce the total cholesterol levels further than sitagliptin (P= 
0.071). The hsCRP level was 1.9±1.2 mg/L in the sitagliptin 
Table 1. Baseline characteristics of the patients
Characteristic Sitagliptin (n=93)
Vildagliptin 
(n=77) P value
Age, yr 61.3±12.9 58.7±12.2 0.186
Sex, male/female 33/60 31/46 0.315
BMI, kg/m2 25.3±3.5 25.3±3.8 0.986
Waist-hip ratio 0.92±0.05 0.92±0.05 0.371
Diabetes duration, yr 6.6±6.7 6.1±4.7 0.642
FPG, mg/dL 144.6±47.3 135.5±32.4 0.153
PPG, mg/dL 240.2±63.2 219.0±60.5 0.030a
HbA1c, % 7.8±1.0 7.6±1.2 0.194
GA, % 19.8±4.2 19.0±4.9 0.304
GA:HbA1c ratio 2.5±0.4 2.5±0.5 0.770
Creatinine, mg/dL 1.0±0.4 1.0±0.4 0.750
eGFR, mL/min/1.73 m2 79.4±20.4 81.4±21.5 0.558
Cholesterol, mg/dL 166.6±72.7 175.9±40.3 0.329
Triglyceride, mg/dL 207.0±27.2 176.7±16.4 0.367
Insulin, μU/mL 11.4±0.9 13.8±2.1 0.240
HOMA-IR 4.0±0.3 4.5±0.6 0.480
C-peptide, ng/mL
   Fasting 2.8±1.5 2.9±1.1 0.764
   Postprandial 2-hour 6.1±2.6 7.1±2.9 0.035a
   ∆C-peptide 3.3±2.2 4.2±2.6 0.030a
HTN 59 (63.4) 46 (59.7) 0.368
CAOD 27 (29.0) 16 (20.8) 0.146
PAOD 3 (3.2) 4 (5.2) 0.396
Stroke 14 (15.1) 11 (14.3) 0.532
Statin 63 (67.6) 34 (44.2) 0.002a
Values are presented as mean±standard deviation or number(%). 
Student t-test was performed.
BMI, body mass index; FPG, fasting plasma glucose; PPG, postpran-
dial glucose; HbA1c, glycated hemoglobin; GA, glycated albumin; 
eGFR, estimated glomerular filtration rate; HOMA-IR, homeostatic 
model assessment-insulin resistance; HTN, hypertension; CAOD, 
coronary artery occlusive disease; PAOD, peripheral artery occlusive 
disease.
aP<0.05.
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group and 1.5±1.4 mg/L in the vildagliptin group at baseline. 
There was no statistical significance difference in the hsCRP 
level after DPP-4 inhibitor treatment.
Proportion of subjects that reached the treatment target 
goal
A decrease in the HbA1c level of over 1% from baseline was 
achieved in 39.8% of the patients administered sitagliptin and 
36.4% of the patients administered vildagliptin (P=0.746) (Fig. 
2A). The proportion of patients exhibiting an HbA1c level of 
less than 7% was 73% in the sitagliptin group and 79.5% in the 
vildagliptin group (P=0.362) (Fig. 2B). There was no signifi-
cant difference between the two groups in terms of glucose 
control. The proportion of patients who achieved a reduction 
in the GA level of over 3% from baseline was 63.6% in the sita-
gliptin group and 50.8% in the vildagliptin group (P=0.136) 
(Fig. 2C). The proportion of patients displaying a GA level of 
less than 14% was 37% in the sitagliptin group and 35% in the 
vildagliptin group (P=0.406) (Fig. 2D).
DISCUSSION
This study compared the effects of sitagliptin and vildagliptin 
on metabolic parameters. The efficacy of sitagliptin and vilda-
gliptin were directly compared based on various glucose and 
lipid parameters over the course of 24 weeks of treatment. We 
found that vildagliptin exerts a similar effect on glucose con-
trol to that of sitagliptin, but vildagliptin exerts more potent 
beneficial effect on the lipid profiles. The metabolic parame-
ters could be easily and consistently measured in most outpa-
Table 2. Drug effects on metabolic parameters after 24 weeks of treatment
Parameter
Sitagliptin (n=93) Vildagliptin (n=77)
Baseline 24 weeks P value Baseline 24 weeks P value
FPG, mg/dL 144.6±47.3 115.7±25.5 0.001 135.5±32.4 115.8±34.3 0.001a
   ∆FPG –28.9±38.9 –17.8±31.4 0.050
PPG, mg/dL 240.2±63.2 194.8±60.5 0.001 219.0±60.5 174.4±61.5 0.001a
   ∆PPG –45.3±72.4 –48.7±68.9 0.764
HbA1c, % 7.8±1.0 6.8±0.8 0.001 7.6±1.2 6.7±0.9 0.001a
   ∆HbA1c –1.0±0.9 –0.9±0.9 0.393
GA, % 19.8±4.2 15.6±3.8 0.001 19.0±4.9 15.4±3.4 0.001a
   ∆GA –4.1±3.8 –3.5±3.7 0.378
GA:HbA1c ratio 2.5±0.4 2.3±0.4 0.001 2.5±0.5 2.3±0.4 0.001a
   ∆GA:HbA1c ratio –0.2±0.3 –0.2±0.3 0.405
Cholesterol, mg/dL
   Total 166.6±72.7 157.4±42.2 0.105 175.9±40.3 160.7±39.6 0.001a
      ∆Total –5.4±34.2 –14.0±30.5 0.071
   HDL 42.1±11.1 41.7±11.2 0.648 44.6±9.5 44.4±10.7 0.103
      ∆HDL –0.3±6.7 –1.4±6.9 0.343
   LDL 81.6±39.4 83.2±32.0 0.935 96.1±34.1 87.7±26.8 0.077
      ∆LDL 0.1±4.01 –7.4±4.1 0.208
Triglyceride, mg/dL 207.0±27.8 170.8±150.7 0.111 176.7±16.4 128.6±68.9 0.001a
   ∆Triglyceride –33.1±19.2 –44.0±13.6 0.656
hsCRP, mg/dL 1.9±1.2 1.4±2.5 0.929 1.5±1.5 1.2±1.1 0.747
   ∆hsCRP –0.3±1.4 –0.1±0.2 0.964
Values are presented as mean±standard deviation. Student paired t-test or t-test was performed.
FPG, fasting plasma glucose; ∆, level at 24 weeks to level at baseline for the given parameter; PPG, postprandial glucose; HbA1c, glycated he-
moglobin; GA, glycated albumin; HDL, high density lipoprotein; LDL, low density lipoprotein; hsCRP, high sensitive C-reactive protein.
aP<0.05.
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tient clinics. There were no significant differences in the 
changes in the glucose parameters. Additionally, a similar pro-
portion of the enrolled patients attained the target glucose 
range after treatment with the DPP-4 inhibitor in both medi-
cation groups. Significant changes in the lipid parameters fol-
lowing sitagliptin treatment were not detected. However, with 
vildagliptin treatment, the total cholesterol and TG levels were 
significantly decreased compared to baseline, although the 
vildagliptin group received a lower amount of statin drug 
compared to the sitagliptin group.
 There are many studies that investigated the clinical efficacy 
of DPP-4 inhibitors [19-24]. Many studies reported an im-
provement in the glucose status compared to placebo when 
administered as a supplement to the existing treatment or as a 
combination therapy with various drugs, including metfor-
min, sulfonylurea, thiazolidinedione, or insulin, in patients 
suffering from type 2 diabetes mellitus with impaired glucose 
control. In addition, the clinical parameters that could affect 
glycemic control were evaluated [10,25,26]. In this study, the 
GA level was used to evaluate the change in glucose metabo-
lism over the course of 2 to 3 weeks as an of index short-dura-
tion glucose control [27]. The GA level is currently widely 
Fig. 1. (A-F) Change in the metabolic parameters during dipeptidyl peptidase-4 (DPP-4) inhibitor treatment. Values are pre-
sented as mean±standard error. SITA, sitagliptin; VILDA, vildagliptin; GA, glycated albumin; HbA1c, glycated hemoglobin; 
FPG, fasting plasma glucose; PPG, postprandial glucose. aP<0.05, compared to baseline.
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used as an index of glycemic control during intensive diabetes 
treatment as a more rapid glycation index than HbA1c for glu-
cose control and excursion [27-29]. In many studies, both 
drugs exerted a similar effect on glucose reduction compared 
to placebo, but some studies reported that vildagliptin may ex-
ert a more potent effect to reduce of oxidative stress and glu-
cose fluctuations, which may play a role in its protection 
against vascular damage [17,30,31]. Recently, a prospective 
randomized control trial reported that sitagliptin and vilda-
gliptin treatment resulted in a reduction in the carotid artery 
intra media thickness (IMT) by decreasing the oxidative stress 
and inflammation marker levels [18]. In that study, there was 
no significant change in the lipid parameters and no difference 
between the two groups in the reduction in the glucose pa-
rameters over the course of 12 weeks of treatment. However, 
vildagliptin induced a stronger reduction in the IMT than si-
tagliptin. Predictors of the IMT change were only found for 
glucose fluctuations, measured as the mean amplitude of glu-
cose excursion and the LDL levels. In our study, there was no 
difference in the change in the glucose parameters, including 
the GA level and the GA to HbA1c ratio. However, there was a 
significant reduction in the lipid parameters in the vildagliptin 
group. Some studies reported this effect of DPP-4 inhibitor 
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Fig. 2. (A-D) Proportion of subjects that reached the target glucose range. Student t-test was performed. SITA, sitagliptin; VIL-
DA, vildagliptin; HbA1c, glycated hemoglobin; ∆HbA1c ≥1, greater than 1% decrease in the HbA1c level from baseline; GA, 
glycated albumin; ∆GA ≥3, greater than 3% decrease in the GA level from baseline. 
treatment on the lipid parameters [17,26,32,33] and found an 
association between DPP-4 inhibitor treatment and reduced 
total cholesterol levels. We investigated the change in lipid pa-
rameters during a 24-week DPP-4 inhibitor treatment period 
and compared the efficacy of the two drugs. Although there 
was no significant difference in the magnitude of the mean 
change between the two groups, vildagliptin treatment result-
ed in significantly reduced levels of total cholesterol and TG.
 This study has some limitations. Because it was not a ran-
domized clinical trial, there were biochemical differences be-
tween the two groups at baseline. We could not exclude the 
possibility of differences in drug compliance between the two 
medications. The number of enrolled patients was relatively 
small because there were few subjects who had not changed 
other oral hypoglycemic medications. Although we continu-
ously followed up for up to 24 weeks, we did not detect a direct 
effect of either drug on the development of CVD. Therefore, 
long-term follow-up studies of diabetes using DPP-4 inhibi-
tors are needed to obtain additional evidence of their benefits.
 In conclusion, vildagliptin exerts a similar effect on meta-
bolic profiles to that of sitagliptin, but vildagliptin exerts a 
more potent beneficial effect on lipid profiles.
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Supplementary Table 1. Lipid profile changes according to statin treatment
Sitagliptin (n=93) Vildagliptin (n=77)
Baseline 24 weeks P value Baseline 24 weeks P value
Statin–
   Total, mg/dL 182.4±40.5 182.0±36.5 0.962 184.9±29.6 173.8±29.3 0.002a
      ∆Total –0.33±36.5 –11.1±21.3 0.175
   HDL, mg/dL 41.6±12.7 42.5±11.6 0.619 46.2±11.2 44.6±10.9 0.184
      ∆HDL 0.9±8.5 –1.6±7.3 0.227
   LDL, mg/dL 90.4±34.5 100.0±32.5 0.105 98.6±30.9 97.6±26.9 0.850
      ∆LDL 9.6±28.0 –0.9±30.6 0.177
   Triglyceride, mg/dL 213.8±44.6 194.4±41.5 0.494 189.4±26.2 138.6±12.1 0.030a
      ∆Triglyceride 0.65±20.3 –18.1±58.6 0.359
Statin+
   Total, mg/dL 162.2±80.7 146.3±40.1 0.091 166.5±51.1 145.8±39.2 0.010a
      ∆Total –7.7±33.2 –20.0±39.6 0.124
   HDL, mg/dL 42.0±11.1 41.1±10.5 0.279 45.2±7.9 44.1±10.5 0.359
      ∆HDL –0.8±5.8 –1.13±6.6 0.824
   LDL, mg/dL 79.8±39.8 75.6±29.2 0.426 90.8±37.6 74.9±21.5 0.025
      ∆LDL –4.2±38.9 –15.9±36.2 0.182
   Triglyceride, mg/dL 199.9±34.9 161.3±14.7 0.123 150.1±84.8 115.1±57.4 0.003a
      ∆Triglyceride –11.5±57.7 –31.2±55.1 0.137
Values are presented as mean±standard deviation. Student paired t-test or t-test was performed.
∆, level at 24 weeks to level at baseline for the given parameter; HDL, high density lipoprotein; LDL, low density lipoprotein.
aP<0.05, compared to baseline.
